Prnewswire Chemomab Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prnewswire chemomab ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prnewswire Chemomab Ltd Today - Breaking & Trending Today

Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors

Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors - read this article along with other careers information, tips and advice on BioSpace ....

Dale Pfost , Irina Koffler , Barbara Lindheim , Jill Quigley , Jillm Quigley , Prnewswire Chemomab Ltd , Chemomab Audit Committee , Gilead Sciences , Lifesci Advisors , Rutgers School Of Law , Chemomab Therapeutics Ltd , Terns Pharmaceuticals , Audit Committee , Strategic Communications , Integra Life Sciences , American University , Legal Affairs , Executive Management , Chief Executive Officer , Chief Operating Officer , Passage Bio , General Counsel , Senior Counsel , Corporate Counsel , Assistant Corporate Counsel , Integra Life ,

Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer

Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace ....

Dale Pfost , Merck Serono , Davidm Weiner , Irina Koffler , Barbara Lindheim , Arnon Aharon , Lumos Pharma , Prnewswire Chemomab Ltd , School Of Medicine , University Of New York At Buffalo , Lifesci Advisors , Brandeis University , Chemomab Therapeutics Ltd , Biomedical Sciences , Strategic Communications , Acadia Pharmaceuticals , Interim Chief Medical Officer , Chief Executive Officer , Chief Medical Officer , Tyr Pharma , State University , New York , Private Securities Litigation Reform , Sci Advisors , Public Relations , Hemomab Therapeutics Names Davidm Weiner ,

Chemomab Completes Merger with Anchiano Therapeutics

Chemomab Completes Merger with Anchiano Therapeutics
USA - English
Combined company will focus on advancing Chemomab s CM-101 currently in Phase 2 for rare fibrotic indications
Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer s Presight Capital and Apeiron Investment Group
News provided by
Share this article
Share this article
TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the completion of its merger with Anchiano Therapeutics Ltd. ( Anchiano ). ....

Christian Angermayer Presight , Irina Koffler , Nissim Darvish , Joel Maryles , Sharon Elkobi , Claude Nicaise , Neil Cohen , Peter Thiel , Goldfarb Seligman , Balan Moses , Stephen Squinto , Wadi Mor , Novo Nordisk , Prnewswire Chemomab Ltd , Apeiron Investment Group , Lifesci Advisors , Oppenheimer Co Inc , Kestrel Therapeutics Inc , Chemomab Therapeutics Ltd , Exchange Commission , Greenberg Traurig , Bristol Myers Squibb , Anchiano Therapeutics Ltd , Business Development , Chemomab Ltd , Anchiano Therapeutics ,

Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis

Share this article
Share this article
TEL AVIV, Israel, Feb. 2, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces enrollment of the first patient in a phase IIa clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC).
The SPRING phase IIa study is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC over 15 weeks of treatment. The study is being conducted at multiple leading sites in the United Kingdom and Israel, and will enroll up to 45 patients randomized in a 2:1 ratio between CM-101 and placebo. ....

City Of , United Kingdom , Peter Thiel , Anchiano Adss , Douglas Thorburn , Wadi Mor , Sharon Elkobi , Company Annual Report On Form , University College London , Prnewswire Chemomab Ltd , Institute For Liver Digestive Health , Anchiano Therapeutics Ltd , Chemomab Ltd , Business Development , Royal Free Hospital , Digestive Health , London United Kingdom , Primary Sclerosing Cholangitis , Anchiano Therapeutics , Information About , Investor Relations , Definitive Proxy Statement , Securities Act , Private Securities Litigation Reform , Annual Report , Quarterly Reports ,